Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer

Breast

Volumn 20, Issue 1, 2011, Pages 39-45

  Gómez, Henry L ^a   Pinto, Joseph A ^a   Olivera, Mivael ^a   Vidaurre, Tatiana ^a   Doimi, Franco D ^a   Vigil, Carlos E ^a   Velarde, Raúl G ^a   Abugattas, Julio E ^a   Alarcón, Edith ^a   Vallejos, Carlos S ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

Anthracycline; Breast cancer; HER2; Markers; Neoadjuvant; Topoisomerase II

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE;

EID: 79451470559     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.06.009     Document Type: Article

References (39)

1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 19(352):930-942. Early Breast Cancer Trialists' Collaborative Group.
2. Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998, 16:3439-3460.
3. Colozza M., Azambuja E., Cardoso F., Sotiriou C., Larsimont D., Piccart M.J. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16:1723-1739.
4. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003, 88:406-412.
5. Aas T., Geisler S., Eide G., Haugen D., Varhaug J., Bassoe A., et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003, 39:438-446.
6. Muss H.B., Thor A.D., Berry D.A., Kute T., Liu E.T., Koerner F., et al. cerb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266.
7. Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90:1361-1370.
8. Dressler L.G., Berry D.A., Broadwater G., Cowan D., Cox K., Griffin S., et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in nodepositive breast cancer patients. J Clin Oncol 2005, 23:4287-4297.
9. Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., Slamon D.J., et al. The effect of her-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997, 15:537-547.
10. Harris L., Yang L., Liotcheva V., Pauli S., Iglehart J., Colvin O., et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001, 7:1497-1504.
11. Coon J., Marcus E., Gupta-Burt S., Seeling S., Jacobson K., Chen S.R., et al. Amplification and overexpression of topoisomerase II-α predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002, 8:1061-1067.
12. Hicks D.G., Yoder B.J., Pettay J., Swain E., Tarr S., Hartke M., et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 2005, 36:348-356.
13. Durbecq V., Paesmans M., Cardoso F., Desmedt C., Di Leo A., Chan S., et al. Correlation between topoisomerase-IIα gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 2004, 25:1473-1479.
14. Di Leo A., Gancberg D., Larsimont D., Tanner M., Jarvinen T., Rouas G., et al. HER2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002, 8:1107-1116.
15. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23:7483-7490. Danish Breast Cancer Cooperative Group.
16. Orlando L., Del Curto B., Gandini S., Ghisini R., Pietri E., Torrisi R., et al. Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008, 17(5):506-511.
17. Arpino G., Ciocca D.R., Weiss H., Allred D.C., Daguerre P., Vargas-Roig L., et al. Predictive value of apoptosis, proliferation, HER2 and topoisomerase II α for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005, 92:69-75.
18. Martin-Richard M., Muñoz J., Albanell L., Colomo M., Bellet M.J., Rey J., et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 2004, 66:388-394.
19. Zhu L., Li Y.F., Chen W.G., He J.R., Peng C.H., Zhu Z.G., et al. HER2 and topoisomerase IIα: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J 2008, 121:1965-1968.
20. Minisini A.M., Di Loreto C., Mansutti M., Artico D., Pizzolitto S., Piga A., et al. Topoisomerase II α and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett 2005, 224:113-139.
21. Petit T., Wilt M., Velten M., Millon R., Rodier J.-F., Borel C., et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004, 40:205-211.
22. Fritz P., Cabrera C.M., Dippon J., Gerteis A., Simon W., Aulitzky W.E., et al. c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res 2005, 374-384.
23. Sobin L.H.W.C. TNM classification of malignant tumours 1997, Wiley-Liss, New York.
24. Di Leo A., Larsimont D., Gancberg D., Jarvinen T., Beauduin M., Vindevoghel A., et al. HER-2 and topo-isomerase Ha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001, 12:1081-1089.
25. Cardoso F., Durbecq V., Larsimont D., Paensmans M., Leroy J., Rouas G., et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004, 201-209.
26. Therasse P., Susan G., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
27. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2:1281-1288.
28. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
29. O'Malley F.P., Chia S., Tu D., Shepherd L., Levine M., Huntsman D., et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer. Breast Cancer Res Treat 2006, 100:S18.
30. Schindlbeck C., Janni W., Shabani N., Kornmeier A., Rack B., Rjosk D., et al. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracycline based therapy: influenced by the HER2- and topoisomerase II alpha-status of the primary tumor?. J Cancer Res Clin Oncol 2005, 131:539-546.
31. MacGrogan G., Rudolph P., de Mascarel I., Mauriac L., Durand M., Avril A., et al. DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 2003, 89:666-671.
32. Durbecq V., Cardoso F. Topoisomerase-II as a predictive marker for response to Anthracyclines. Adv Oncol November 2007, 49-57.
33. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levine M.N., Bramwell V.H., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009, 101:644-650.
34. Nielsen K.V., Ejlertsen B., Müller S., Jürgensen J.T., Knoop A., Knudsen H., et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 2008, 47:725-734.
35. Tubbs R., Barlow W.E., Budd G.T., Swain E., Porter P., Gown A., et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 2009, 27:3881-3886.
36. Pritchard K.I. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?. JCO 2009, 27:3875-3876.
37. Therasse P., Mauriac L., Welnicka-Jaskiewicz M., Bruning P., Cufer T., Bonnefoi H., et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide+filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003, 21:843-850.
38. Petit T., Borel C., Ghnassia J.P., Rodier J.F., Escande A., Mors R., et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001, 7:1577-1581.
39. Harris L.N., Broadwater G., Abu-Khalaf M., Cowan D., Thor A.D., Budman D., et al. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 2009, 27:3430-3436.